Is Farxiga Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Farxiga? Is Farxiga safe for nursing mother and child? Does Farxiga extracts into breast milk? Does Farxiga has any long term or short term side effects on infants? Can Farxiga influence milk supply or can Farxiga decrease milk supply in lactating mothers?

• DrLact safety Score for Farxiga is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Farxiga may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Farxiga may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Farxiga .
• It is recommended to evaluate the advantage of not breastfeeding while using Farxiga Vs not using Farxiga And continue breastfeeding.
• While using Farxiga Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Farxiga is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014).Administered orally once a day. Low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (EMA 2017, Plosker 2014). Since the last update, we have not found published data on its excretion in breast milk. Its high percentage of protein binding (EMA 2017) makes its transfer to milk in significant quantities unlikely, but the low molecular weight and its elimination half-life greater than 12 hours could facilitate a possible transfer. Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. Diet, exercise and breastfeeding improve blood glucose levels.

No information is available on the clinical use of Farxiga during breastfeeding. Farxiga is an uncharged molecule that is 91% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. The manufacturer does not recommend Farxiga during breastfeeding because of a theoretical risk to the infant's developing kidney. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.